30 Jan, 2024 Regulation of Life Sciences AI in Australia By Nicholas Tyacke Alexandra de Zwart Alex Horder Jordan Davis +1 more... Show less In an important development for life sciences and healthcare companies (et al), on 17 January 2024 and after receiving over 500...
29 Jan, 2024 Commission report finds active competition enforcement continues to contribute to affordable and innovative medicines By Joost Haans Anna Sacco On 26 January 2024, the European Commission published a report providing an overview of the enforcement of EU antitrust and merger rules...
23 Jan, 2024 “March-in” rights and life sciences inventions in Australia: Is the position in Australia the same as under the US Bayh-Dole Act? By Nicholas Tyacke Greg Bodulovic Jess McKenna Recent statements and actions by the US Biden Administration regarding march-in rights and drug pricing have made these issues a hot...
23 Jan, 2024 Understanding what is happening in the life sciences, healthcare and cannabis market in Brazil in 2024 and why By Bruna Rocha Victoria Cristofaro Juliana Marcondes Transactional. The years 2022 and 2023 presented significant challenges for the industry, with a post-pandemic market correction and...
15 Jan, 2024 Poland - Life Sciences Monthly Brief, December 2023 By Andrzej Balicki, Ph.D. Jolanta Dabrowicz Przemysław Matuszewski Urszula Grębowska +1 more... Show less Download a copy of our December monthly briefing, which covers key updates and insights in the following areas: Medical products;...
08 Jan, 2024 Portugal | Removal of the retail price of medicines from labelling and packaging By Mariana Ricardo Since 2006, when the Medicines Code was approved in Portugal, marketing authorisation holders had to include the retail selling price of...
03 Jan, 2024 European Medicines Agency publishes five-year AI workplan By Coran Darling Keo Shaw Danny Tobey Marco de Morpurgo +1 more... Show less On December 18, 2023, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) published their 2023-2028...